Loading...
Market
What will be the first commercial application of NK cell enhancement by end of 2026?
2
Resolution / Starting Odds
Therapeutic use in hospitals • 25%
Research tool for labs • 25%
No commercial application • 25%
Other • 25%
Press releases from biotech companies and regulatory announcements
Story
Penn State Researchers Enhance NK Cells to Target Solid Tumors; Science Study Reveals Dendritic Cell Transformation
Oct 27, 2024, 05:34 AM
Researchers from Penn State Hershey have developed a method to enhance immune cells' ability to target solid tumors. By creating a light-activated switch that controls the protein septin-7, the team incorporated this innovation into natural killer (NK) cells, allowing them to penetrate and kill tumor cells grown in laboratory settings. Additionally, a study published in Science reveals that cancer cells can be reprogrammed in vivo into dendritic cells, which can activate T cells and promote antitumor immunity. This transformation utilizes transcription factors such as PU.1, IRF8, and BATF3, enabling the modified cells to present antigens and stimulate cancer-specific T cell responses. Furthermore, researchers at the Wyss Institute have developed a metabolic labeling technology that enhances T cells' persistence in solid tumors by attaching immune-boosting cytokines directly to them, thereby improving their cancer-fighting capabilities.
View original story
Similar markets
Treatment of A. baumannii infections • 25%
Treatment of other bacterial infections • 25%
Pandemic preparedness • 25%
Other • 25%
Cancer research • 25%
Drug development • 25%
Genetic disease research • 25%
Other applications • 25%
Successful Phase I trial • 25%
FDA Fast Track designation • 25%
Publication of promising preclinical results • 25%
No major milestone achieved • 25%
NTLA-2002 • 25%
Editas Medicine Therapy • 25%
Beam Therapeutics Therapy • 25%
Other • 25%
Improved efficacy • 25%
Reduced side effects • 25%
Lower cost of treatment • 25%
Other • 25%
Drug Development • 25%
Disease Diagnosis • 25%
Biosensor Technology • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Breast Cancer Diagnosis • 25%
Lung Cancer Diagnosis • 25%
Prostate Cancer Diagnosis • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
Chronic Disease Management • 25%
Mental Health • 25%
Telemedicine • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%